

# QUALITY OF LIFE OF PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS UNDERGOING OUT-PATIENT TREATMENT WITH DUPILUMAB

I. Casas Hidalgo<sup>1</sup>, A. Rodríguez Delgado<sup>1</sup>, R. Álvarez Sánchez<sup>1</sup>, A. Madrid Paredes<sup>1</sup>

1.Complejo Hospitalario Universitario San Cecilio



## BACKGROUND

Dupilumab, a human anti-interleukin-4 receptor alpha monoclonal antibody, is the first biologic therapy to have been approved for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD). It is a disabling disease characterized by the presence of severe pruritus which can lead to sleep disturbance, anxiety and depression.

## PURPOSE

To assess the improvement in the quality of life of patients with moderate-to-severe AD undergoing out-patient treatment with Dupilumab in our hospital.

## RESULTS

6 patients (83% male) were treated with Dupilumab. The average age was  $48,86 \pm 14,30$ . The average of the duration of treatment with Dupilumab was 27(20-38) weeks.


		Number of patients (%) previous of treatment with Dupilumab	Number of patients (%) after the treatment with Dupilumab	
SCORAD index	mild disease score (SCORAD<25)	0 (0%)	2 (33%)	
	moderate disease score (25<SCORAD<50)	1 (17%)	3 (50%)	
	severe disease score (SCORAD>50)	5 (83%)	1 (17%)	
DLQI questionnaire	0-1 (no effect at all on patient's life)	1 (17%)	3 (50%)	
	2-5 (small effect on patient's life)	0 (0%)	1 (17%)	
	6-10 (moderate effect on patient's life)	0 (0%)	1 (17%)	
	11-20 (very large effect on patient's life)	1 (17%)	1 (17%)	
	21-30 (extremely very large effect on patient's life)	4 (66%)	0 (0%)	
	HADS questionnaire	depression (D)	0-7 (normal)	3 (50%)
8-10 (borderline abnormal)			0 (0%)	1 (17%)
11-21 (abnormal)			3 (50%)	0 (0%)
anxiety (A)		0-7 (normal)	1 (17%)	3 (50%)
		8-10 (borderline abnormal)	1 (17%)	2 (33%)
		11-21 (abnormal)	4 (66%)	1 (17%)

## MATERIAL AND METHODS

Retrospective observational study (December 2017-September 2018), including all patients who received Dupilumab, was conducted. Two specific validated questionnaire were used: DLQI and HADS, with complete confidentiality ensured. In addition, other variables were analyzed: age, sex, severity of AD (SCORAD index) as well as duration of treatment with Dupilumab.

## CONCLUSION

In accordance with the results of DLQI and HADS questionnaires, Dupilumab has a substantial impact on the health-related quality of life (HRQoL) of patients with moderate-to-severe atopic dermatitis.



<http://www.eahp.eu/24-4CPS-038>

